Physician profile
Abdul Aziz
NPI 1811973696
$23,000.09
in general payments reported to CMS, 2019-2025
30 companies · $3,915 in 2025
The $3,915 reported for 2025 was more than what 82% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,942 · 2020: $2,989 · 2021: $3,107 · 2022: $3,049 · 2023: $3,479 · 2024: $3,519 · 2025: $3,915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,912.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $4,322.57 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Abbvie INC. | $3,424.73 | 2019-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $2,652.69 | 2019-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $1,980.91 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,513.70 | 2019-2025 | |
| Lilly USA, LLC | $1,385.37 | 2019-2024 | Taltz |
| Mallinckrodt Hospital Products INC. | $1,027.22 | 2020-2025 | Acthar |
| Janssen Biotech, INC. | $844.75 | 2019-2025 | Tremfya, Stelara, Remicade |
| Astrazeneca Pharmaceuticals LP | $838.32 | 2021-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $776.28 | 2019-2025 | Benlysta, Nucala |
| E.R. Squibb & Sons, L.L.C. | $646.94 | 2019-2025 | Orencia |
| Horizon Therapeutics Plc | $617.00 | 2019-2023 | Krystexxa |
| Radius Health, INC. | $498.57 | 2020-2025 | Tymlos |
| Genzyme Corporation | $444.46 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $355.57 | 2021-2025 | Lupkynis |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $271.21 | 2019 | |
| Alexion Pharmaceuticals, INC. | $218.14 | 2021-2025 | Strensiq |
| Janssen Pharmaceuticals, INC | $160.90 | 2019 | |
| Sobi, INC | $160.01 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.32 | 2019-2024 | Cyltezo |
| Sandoz INC. | $149.62 | 2023-2024 | Hyrimoz |
| Medexus Pharma, INC. | $133.41 | 2019-2020 | |
| Fresenius Kabi USA, LLC | $129.34 | 2023-2025 | Idacio, Tyenne |
| Antares Pharma, INC. | $92.20 | 2019-2021 | |
| Organon LLC | $87.86 | 2022-2024 | |
| Genentech USA, INC. | $40.58 | 2021-2025 | Actemra |
| Ultragenyx Pharmaceutical INC. | $24.11 | 2021 | |
| Ani Pharmaceuticals, INC. | $16.15 | 2022 | |
| Ascend Therapeutics US, LLC | $14.82 | 2020 | |
| Celgene Corporation | $13.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Aziz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.